Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 5, 2026, 2:31 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,378 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Respiratory Complication Clear all
Completed No phase listed Observational Accepts healthy volunteers Results available

Risk Factors, Costs, and Impacts of ED Boarding

NCT07532564
View directory record Official record
Conditions
Stroke (CVA) or TIA, Diabetes, Asthma (Diagnosis), COPD (Chronic Obstructive Pulmonary Disease), Sepsis, Hypertension, Heart Failure, Pneumonia, Urinary Tract Infection (Diagnosis), Chest Pain, Psychiatric Disorder, Sickle Cell Disease (SCD)
Interventions
Not listed
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
30,486 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Sep 5, 2026, 2:31 PM EDT
Active, not recruiting Phase 2Phase 3 Interventional

A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study to Determine the Safety and Effectiveness of Azeliragon in the Treatment of Patients Hospitalized for Coronavirus Disease 2019 (COVID-19) or Pneumonia

NCT05815485
View directory record Official record
Conditions
COVID-19
Interventions
Azeliragon, Placebo
Drug
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
18 Years and older
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
3
States / cities
Chicago, Illinois • Ann Arbor, Michigan • Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 2, 2025 · Synced Sep 5, 2026, 2:31 PM EDT
Completed Phase 1 Interventional

Cyclophosphamide or Denileukin Diftitox Followed By Expanding a Patient's Own T Cells in the Laboratory in Treating Patients With HER-2/Neu Overexpressing Metastatic Breast Cancer, Ovarian Cancer, or Non-Small Cell Lung Cancer Previously Treated With HER-2/Neu Vaccine

NCT00228358
View directory record Official record
Conditions
HER2-positive Breast Cancer, Recurrent Breast Cancer, Recurrent Non-small Cell Lung Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Ovarian Germ Cell Tumor, Stage IV Breast Cancer, Stage IV Non-small Cell Lung Cancer, Stage IV Ovarian Epithelial Cancer, Stage IV Ovarian Germ Cell Tumor
Interventions
ex vivo-expanded HER2-specific T cells, cyclophosphamide, denileukin diftitox, flow cytometry, immunoenzyme technique
Drug · Biological · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 10, 2014 · Synced Sep 5, 2026, 2:31 PM EDT
Completed Not applicable Interventional

Prematurity Related Ventilatory Control (PRE-VENT) - Specific Aim 3

NCT03333174
View directory record Official record
Conditions
Infant,Premature
Interventions
Cardiorespiratory monitoring
Diagnostic Test
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
1 Day to 98 Days
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Sep 20, 2021 · Synced Sep 5, 2026, 2:31 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

The Effects of General Anesthetics on Upper Airway Collapsibility in Healthy Subjects

NCT01557920
View directory record Official record
Conditions
Airway Complication of Anaesthesia, Healthy
Interventions
Propofol, Sevoflurane
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 45 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 12, 2016 · Synced Sep 5, 2026, 2:31 PM EDT
Active, not recruiting Phase 1 Interventional

A Study Evaluating AB248 Alone or in Combination With Pembrolizumab in Adult Patients With Solid Tumors

NCT05653882
View directory record Official record
Conditions
Solid Tumor, Non Small Cell Lung Cancer, Melanoma, Squamous Cell Carcinoma of Head and Neck, Renal Cell Carcinoma
Interventions
etakafusp alfa (AB248), pembrolizumab
Biological
Lead sponsor
Asher Biotherapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
552 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
20
States / cities
Duarte, California • Los Angeles, California • San Diego, California + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2025 · Synced Sep 5, 2026, 2:31 PM EDT
Recruiting Phase 1 Interventional

KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer

NCT05483491
View directory record Official record
Conditions
Gastric Cancer, Breast Cancer, Cervical Cancer, Lung Cancer
Interventions
KK-LC-1 TCR-T cells, Aldesleukin
Biological · Drug
Lead sponsor
Christian Hinrichs
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
2
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Sep 5, 2026, 2:31 PM EDT
Terminated Not applicable Interventional

EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung Cancer

NCT00087191
View directory record Official record
Conditions
Advanced Adult Primary Liver Cancer, Carcinoma of the Appendix, Fallopian Tube Cancer, Gastrointestinal Stromal Tumor, Localized Extrahepatic Bile Duct Cancer, Localized Gallbladder Cancer, Localized Gastrointestinal Carcinoid Tumor, Localized Resectable Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer, Metastatic Gastrointestinal Carcinoid Tumor, Ovarian Sarcoma, Ovarian Stromal Cancer, Primary Peritoneal Cavity Cancer, Recurrent Adult Primary Liver Cancer, Recurrent Adult Soft Tissue Sarcoma, Recurrent Colon Cancer, Recurrent Extrahepatic Bile Duct Cancer, Recurrent Gallbladder Cancer, Recurrent Gastric Cancer, Recurrent Gastrointestinal Carcinoid Tumor, Recurrent Non-small Cell Lung Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Ovarian Germ Cell Tumor, Recurrent Pancreatic Cancer, Recurrent Rectal Cancer, Recurrent Small Intestine Cancer, Recurrent Uterine Sarcoma, Regional Gastrointestinal Carcinoid Tumor, Small Intestine Adenocarcinoma, Small Intestine Leiomyosarcoma, Small Intestine Lymphoma, Stage 0 Non-small Cell Lung Cancer, Stage I Adult Soft Tissue Sarcoma, Stage I Colon Cancer, Stage I Gastric Cancer, Stage I Non-small Cell Lung Cancer, Stage I Ovarian Epithelial Cancer, Stage I Ovarian Germ Cell Tumor, Stage I Pancreatic Cancer, Stage I Rectal Cancer, Stage I Uterine Sarcoma, Stage II Adult Soft Tissue Sarcoma, Stage II Colon Cancer, Stage II Gastric Cancer, Stage II Non-small Cell Lung Cancer, Stage II Ovarian Epithelial Cancer, Stage II Ovarian Germ Cell Tumor, Stage II Pancreatic Cancer, Stage II Rectal Cancer, Stage II Uterine Sarcoma, Stage III Adult Soft Tissue Sarcoma, Stage III Colon Cancer, Stage III Gastric Cancer, Stage III Ovarian Epithelial Cancer, Stage III Ovarian Germ Cell Tumor, Stage III Pancreatic Cancer, Stage III Rectal Cancer, Stage III Uterine Sarcoma, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Adult Soft Tissue Sarcoma, Stage IV Colon Cancer, Stage IV Gastric Cancer, Stage IV Non-small Cell Lung Cancer, Stage IV Ovarian Epithelial Cancer, Stage IV Ovarian Germ Cell Tumor, Stage IV Pancreatic Cancer, Stage IV Rectal Cancer, Stage IV Uterine Sarcoma, Unresectable Extrahepatic Bile Duct Cancer, Unresectable Gallbladder Cancer
Interventions
EF5, motexafin lutetium, pharmacological study
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 15, 2013 · Synced Sep 5, 2026, 2:31 PM EDT
Not yet recruiting Early Phase 1 Interventional Accepts healthy volunteers

Evaluation of the Distribution of 64Cu/68Ga Labeled CM500 in Healthy Volunteers and Patients With Cancer

NCT07781852
View directory record Official record
Conditions
Bladder Cancer, Glioma, Glioblastoma (GBM), Breast Cancer, Colorectal Cancer, Esophageal Cancer, Gastric Cancer (GC), Pharynx Cancer, Oral Cavity Cancer, Kidney Cancer, Liver Cancer, Lung Cancer (NSCLC), Ovarian Cancer, Pancreatic Cancer, PDAC - Pancreatic Ductal Adenocarcinoma, Prostate Cancer
Interventions
[64Cu]CM500, [68Ga]CM500, PET/MR, PET/CT, Blood Collection
Drug · Device · Procedure
Lead sponsor
Lumina Pharmaceuticals Inc
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
3
States / cities
Boston, Massachusetts • Grand Rapids, Michigan • New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Sep 5, 2026, 2:31 PM EDT
Recruiting No phase listed Observational

Improving Patient-Centered Care for Underserved Older African American Patients With Cardiovascular Comorbidities

NCT07748858
View directory record Official record
Conditions
Cardiovascular, Comorbidity, Diabetes, Inflammatory Joint Diseases, Chronic Kidney Diease, Chronic Obstructive Pulmonary Disease (COPD), Cardiovascular Disease
Interventions
Not listed
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
50 Years to 99 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Sep 5, 2026, 2:31 PM EDT
Withdrawn No phase listed Observational

Intraop Ventilation Management and Postop Pulmonary Complications in High Risk Patients for OSA

NCT03135691
View directory record Official record
Conditions
Ventilator-Induced Lung Injury
Interventions
Not listed
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 26, 2025 · Synced Sep 5, 2026, 2:31 PM EDT
Completed Phase 1 Interventional Results available

A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors

NCT04853017
View directory record Official record
Conditions
Minimal Residual Disease, KRAS G12D, KRAS G12R, NRAS G12D, NRAS G12R, Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, Non-small Cell Lung Cancer, Ovarian Cancer, Cholangiocarcinoma, Bile Duct Cancer, Gallbladder Carcinoma
Interventions
ELI-002 2P
Drug
Lead sponsor
Elicio Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
10
States / cities
Duarte, California • Los Angeles, California • Aurora, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2025 · Synced Sep 5, 2026, 2:31 PM EDT
Completed Phase 1 Interventional

Topotecan Liposomes Injection for Small Cell Lung Cancer (SCLC), Ovarian Cancer and Other Advanced Solid Tumors

NCT00765973
View directory record Official record
Conditions
Small Cell Lung Cancer, Ovarian Cancer, Solid Tumors
Interventions
Topotecan Liposomes Injection (TLI)
Drug
Lead sponsor
Spectrum Pharmaceuticals, Inc
Industry
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
2
States / cities
Detroit, Michigan • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 12, 2020 · Synced Sep 5, 2026, 2:31 PM EDT
Active, not recruiting Phase 1 Interventional

Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies

NCT05783622
View directory record Official record
Conditions
Non-Small Cell Lung Cancer, Renal Cell Carcinoma, Squamous Cell Carcinoma of the Head and Neck, Colorectal Carcinoma, Small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma, Triple-negative Breast Cancer
Interventions
JANX008
Drug
Lead sponsor
Janux Therapeutics
Industry
Eligibility
18 Years to 100 Years
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
18
States / cities
Duarte, California • Sacramento, California • San Diego, California + 15 more
Source: ClinicalTrials.gov public record
Updated May 31, 2026 · Synced Sep 5, 2026, 2:31 PM EDT
Completed Phase 1 Interventional

RAV12 in Treating Patients With Metastatic or Recurrent Adenocarcinoma

NCT00101972
View directory record Official record
Conditions
Cancer
Interventions
monoclonal antibody RAV12
Biological
Lead sponsor
MacroGenics
Industry
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
5
States / cities
Santa Monica, California • Washington D.C., District of Columbia • Miami, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2022 · Synced Sep 5, 2026, 2:31 PM EDT
Completed Not applicable Interventional

Physical Activities by Technology Help (PATH)

NCT03212079
View directory record Official record
Conditions
Breast Cancer, Prostate Cancer, Lung Cancer, Colorectal Cancer, Cervical Cancer, Oral Cancer
Interventions
Mycoach Smart Text, MyCoach on Amazon Alexa
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 80 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 6, 2018 · Synced Sep 5, 2026, 2:31 PM EDT
Completed Not applicable Interventional

Physician-Initiated Stop-Smoking Program for Patients Receiving Treatment for Early-Stage Cancer

NCT00002520
View directory record Official record
Conditions
Bladder Cancer, Breast Cancer, Colorectal Cancer, Head and Neck Cancer, Lung Cancer, Lymphoma, Prostate Cancer, Testicular Germ Cell Tumor, Tobacco Use Disorder, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
nicotine, Usual Care
Drug · Behavioral
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
19 Years to 120 Years
Enrollment
434 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1990
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 14, 2023 · Synced Sep 5, 2026, 2:31 PM EDT
Not listed No phase listed Observational

Perioperative Vaping Complications

NCT05912023
View directory record Official record
Conditions
Vaping, Complication of Anesthesia
Interventions
Not listed
Lead sponsor
Navy Medical Center San Diego
Federal
Eligibility
12 Years to 80 Years
Enrollment
300 participants
Timeline
2023 – 2025
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated May 16, 2024 · Synced Sep 5, 2026, 2:31 PM EDT
Completed No phase listed Observational

Collecting Tumor Samples From Patients With Gynecological Tumors

NCT00897442
View directory record Official record
Conditions
Borderline Ovarian Clear Cell Tumor, Borderline Ovarian Serous Tumor, Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Small Cell Carcinoma, Cervical Squamous Cell Carcinoma, Not Otherwise Specified, Childhood Embryonal Rhabdomyosarcoma, Childhood Malignant Ovarian Germ Cell Tumor, Endometrioid Stromal Sarcoma, Gestational Trophoblastic Tumor, Malignant Mesothelioma, Malignant Ovarian Epithelial Tumor, Melanoma, Neoplasm of Uncertain Malignant Potential, Ovarian Brenner Tumor, Ovarian Clear Cell Cystadenocarcinoma, Ovarian Serous Cystadenocarcinoma, Paget Disease of the Vulva, Recurrent Cervical Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Ovarian Germ Cell Tumor, Recurrent Primary Peritoneal Carcinoma, Recurrent Uterine Corpus Carcinoma, Recurrent Vaginal Carcinoma, Recurrent Vulvar Carcinoma, Stage I Ovarian Cancer, Stage I Uterine Corpus Cancer, Stage I Vaginal Cancer, Stage I Vulvar Cancer, Stage IA Cervical Cancer, Stage IA Fallopian Tube Cancer, Stage IA Ovarian Cancer, Stage IA Ovarian Germ Cell Tumor, Stage IB Cervical Cancer, Stage IB Fallopian Tube Cancer, Stage IB Ovarian Cancer, Stage IB Ovarian Germ Cell Tumor, Stage IC Fallopian Tube Cancer, Stage IC Ovarian Cancer, Stage IC Ovarian Germ Cell Tumor, Stage II Ovarian Cancer, Stage II Uterine Corpus Cancer, Stage II Vaginal Cancer, Stage II Vulvar Cancer, Stage IIA Cervical Cancer, Stage IIA Fallopian Tube Cancer, Stage IIA Ovarian Cancer, Stage IIA Ovarian Germ Cell Tumor, Stage IIB Cervical Cancer, Stage IIB Fallopian Tube Cancer, Stage IIB Ovarian Cancer, Stage IIB Ovarian Germ Cell Tumor, Stage IIC Fallopian Tube Cancer, Stage IIC Ovarian Cancer, Stage IIC Ovarian Germ Cell Tumor, Stage III Borderline Ovarian Surface Epithelial-Stromal Tumor, Stage III Cervical Cancer, Stage III Uterine Corpus Cancer, Stage III Vaginal Cancer, Stage III Vulvar Cancer, Stage IIIA Fallopian Tube Cancer, Stage IIIA Ovarian Cancer, Stage IIIA Ovarian Germ Cell Tumor, Stage IIIA Primary Peritoneal Cancer, Stage IIIB Fallopian Tube Cancer, Stage IIIB Ovarian Cancer, Stage IIIB Ovarian Germ Cell Tumor, Stage IIIB Primary Peritoneal Cancer, Stage IIIC Fallopian Tube Cancer, Stage IIIC Ovarian Cancer, Stage IIIC Ovarian Germ Cell Tumor, Stage IIIC Primary Peritoneal Cancer, Stage IV Borderline Ovarian Surface Epithelial-Stromal Tumor, Stage IV Fallopian Tube Cancer, Stage IV Ovarian Cancer, Stage IV Primary Peritoneal Cancer, Stage IV Uterine Corpus Cancer, Stage IVA Cervical Cancer, Stage IVA Vaginal Cancer, Stage IVB Cervical Cancer, Stage IVB Vaginal Cancer, Stage IVB Vulvar Cancer, Uterine Corpus Cancer, Uterine Corpus Leiomyosarcoma, Vulvar Squamous Cell Carcinoma
Interventions
Laboratory Biomarker Analysis
Other
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
Female only
Enrollment
275 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1992
U.S. locations
187
States / cities
Fayetteville, Arkansas • Little Rock, Arkansas • Burbank, California + 128 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2016 · Synced Sep 5, 2026, 2:31 PM EDT
Active, not recruiting Not applicable Interventional

Discharge Stewardship in Children's Hospitals

NCT05826873
View directory record Official record
Conditions
Pneumonia, Bacterial, Pneumonia Childhood, Urinary Tract Infections, Soft Tissue Infections, Skin Infections, Community-acquired Pneumonia
Interventions
Discharge antibiotic stewardship intervention
Behavioral
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
28 Days to 18 Years
Enrollment
1,131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
5
States / cities
St Louis, Missouri • Philadelphia, Pennsylvania • Salt Lake City, Utah + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2026 · Synced Sep 5, 2026, 2:31 PM EDT
Not yet recruiting Phase 2 Interventional

Pressure Targeting During High Flow Therapy in Premature Infants

NCT07418502
View directory record Official record
Conditions
Preterm Infants, Respiratory Distress Syndrome (Neonatal), BPD - Bronchopulmonary Dysplasia
Interventions
Pressure Targeted High Flow, CPAP
Procedure
Lead sponsor
University of Texas at Austin
Other
Eligibility
7 Days to 40 Weeks
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
2
States / cities
San Diego, California • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Sep 5, 2026, 2:31 PM EDT
Recruiting Phase 1 Interventional

Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors

NCT05856981
View directory record Official record
Conditions
Solid Tumor, Adult, Metastatic Solid Tumor, Refractory Cancer, CRC, Colorectal Cancer, RCC, Clear Cell Adenocarcinoma, NSCLC (Advanced Non-small Cell Lung Cancer), Endometrial Cancer
Interventions
ADU-1805, Pembrolizumab
Drug
Lead sponsor
Sairopa B.V.
Industry
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
4
States / cities
Detroit, Michigan • St Louis, Missouri • Canton, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Sep 5, 2026, 2:31 PM EDT
Terminated Not applicable Interventional Results available

Entrainment-Based Mechanical Ventilation

NCT03512067
View directory record Official record
Conditions
Respiratory Insufficiency, Respiratory Failure, Mechanical Ventilation Complication
Interventions
Patients given EMV Ventilation
Device
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 10, 2019 · Synced Sep 5, 2026, 2:31 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Study on the Incidence of Influenza and Its Complications, in Subjects Aged 50 Years and Over Vaccinated With Fluarix™

NCT00377611
View directory record Official record
Conditions
Influenza
Interventions
Fluarix™
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
50 Years and older
Enrollment
3,054 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
9
States / cities
Mobile, Alabama • Delray Beach, Florida • Pembroke Pines, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2018 · Synced Sep 5, 2026, 2:31 PM EDT